Technical Analysis for BCLI - Brainstorm Cell Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 3.47 0.00% 0.00
BCLI closed unchanged on Friday, January 18, 2019, on 25 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical BCLI trend table...

Date Alert Name Type % Chg
Jan 18 Calm After Storm Range Contraction 0.00%
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 NR7-2 Range Contraction 0.00%
Jan 17 Boomer Buy Setup Bullish Swing Setup 0.00%
Jan 17 Calm After Storm Range Contraction 0.00%
Jan 17 Narrow Range Bar Range Contraction 0.00%
Jan 17 NR7 Range Contraction 0.00%
Jan 17 NR7-2 Range Contraction 0.00%
Jan 16 Calm After Storm Range Contraction 0.58%

Older signals for BCLI ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.
Is BCLI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.35
52 Week Low 2.88
Average Volume 59,316
200-Day Moving Average 3.7337
50-Day Moving Average 3.2168
20-Day Moving Average 3.3885
10-Day Moving Average 3.435
Average True Range 0.1501
ADX 42.9
+DI 26.7685
-DI 6.6552
Chandelier Exit (Long, 3 ATRs ) 3.2497
Chandelier Exit (Short, 3 ATRs ) 3.4303
Upper Bollinger Band 3.6449
Lower Bollinger Band 3.1321
Percent B (%b) 0.66
BandWidth 15.13354
MACD Line 0.0732
MACD Signal Line 0.0687
MACD Histogram 0.0045
Fundamentals Value
Market Cap 65.38 Million
Num Shares 18.8 Million
EPS -0.32
Price-to-Earnings (P/E) Ratio -10.84
Price-to-Sales 0.00
Price-to-Book 15.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.55
Resistance 3 (R3) 3.55 3.53 3.53
Resistance 2 (R2) 3.53 3.51 3.53 3.53
Resistance 1 (R1) 3.50 3.50 3.49 3.50 3.52
Pivot Point 3.48 3.48 3.48 3.48 3.48
Support 1 (S1) 3.45 3.46 3.44 3.45 3.42
Support 2 (S2) 3.43 3.45 3.43 3.41
Support 3 (S3) 3.40 3.43 3.41
Support 4 (S4) 3.40